F2RL1 and metabolic dysfunction-associated steatotic liver disease: Further studies are warranted in order to confirm whether the PAR2 inhibitor 1-PPA could be considered a clinically relevant strategy for NASH treatment and possibly, also for the modulation of liver cancer development, a growing risk in patients with non-alcoholic fatty liver disease, even in the absence of cirrhosis [53].